Genmab says Arzerra leukaemia test result positive
COPENHAGEN |
COPENHAGEN Aug 12 (Reuters) - Denmark's Genmab (GEN.CO) announced positive results from a Phase II study of Arzerra (ofatumumab) to treat chronic lymphocytic leukaemia (CLL) in previously untreated patients.
Arzerra, which is being co-developed by GlaxoSmithKline (GSK.L), was given in combination with fludarabine and cyclophosphamide (FC) to 61 patients.
The overall response rate was 77 percent in a 500 mg treatment group and 73 percent in a 1000 mg treatment group. There were no unexpected safety findings, Genmab said late on Tuesday.
(Reporting by Teis Jensen; editing by John Stonestreet)
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters